Association Between miR-539 and miR-6824 and Their Target Gene, MAP2K1, Expression Level in Oral Cancer

No abstract is available for this paper.

• Publication year

  2025

• Venue

  Indian Journal of Surgical Oncology

• Publication date

  2025-05-03

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s13193-025-02292-xPMID 41726034PMCID PMC12921061
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• MiR-195 Enhances the Sensitivity of Oral Cancer Cells to Cisplatin (DDP) by Down-Regulating the Expression of MAPK Kinase 1 (MEK1)

  2020cited by this paper
• Role of Oncogenes and Tumor-suppressor Genes in Carcinogenesis: A Review

  2020cited by this paper
• Molecular Mechanisms of Bortezomib Action: Novel Evidence for the miRNA–mRNA Interaction Involvement

  2020cited by this paper
• miR-330-3p suppresses liver cancer cell migration by targeting MAP2K1.

  2019cited by this paper
• MiR-539 functions as a tumor suppressor in pancreatic cancer by targeting TWIST1.

  2019cited by this paper
• miR-181a down-regulates MAP2K1 to enhance adriamycin sensitivity in leukemia HL-60 cells.

  2019influential reference
• Association of MAPK and its regulatory miRNAs (603, 4301, 8485, and 4731) with the malignant transformation of oral lichen planus

  2019cited by this paper
• MAP2K1 is a potential therapeutic target in erlotinib resistant head and neck squamous cell carcinoma

  2019cited by this paper
• A Comprehensive Review on MAPK: A Promising Therapeutic Target in Cancer

  2019cited by this paper
• Downregulation miR-539 is associated with poor prognosis of gastric cancer patients and aggressive progression of gastric cancer cells

  2019cited by this paper
• MicroRNA‐539 functions as a tumour suppressor in prostate cancer via the TGF‐β/Smad4 signalling pathway by down‐regulating DLX1

  2019cited by this paper
• The Anti-Cancer Effect of Quercetin: Molecular Implications in Cancer Metabolism

  2019cited by this paper
• Effect of exosomal miRNA on cancer biology and clinical applications

  2018cited by this paper
• miR-539 suppresses proliferation and induces apoptosis in renal cell carcinoma by targeting high mobility group A2

  2018cited by this paper
• Down-regulation of MAP2K1 by miR-539 inhibits hepatocarcinoma progression.

  2018cited by this paper
• miR-539 enhances chemosensitivity to cisplatin in non-small cell lung cancer by targeting DCLK1.

  2018cited by this paper
• miR-539 acts as a tumor suppressor by targeting epidermal growth factor receptor in breast cancer

  2018cited by this paper
• Diagnostic and prognostic relevance of salivary microRNA-21, -125a, -31 and -200a levels in patients with oral lichen planus - a short report

  2018cited by this paper
• MiR-539 inhibits proliferation and migration of triple-negative breast cancer cells by down-regulating LAMA4 expression

  2018cited by this paper
• miR‐200c‐3p spreads invasive capacity in human oral squamous cell carcinoma microenvironment

  2018cited by this paper
• Oral cancer in South East Asia: Current status and future directions

  2017cited by this paper
• The ERK/MAPK pathway is overexpressed and activated in gallbladder cancer.

  2017cited by this paper
• Novel insights into epigenetic drivers of oropharyngeal squamous cell carcinoma: role of HPV and lifestyle factors

  2017cited by this paper
• Current mouse models of oral squamous cell carcinoma: Genetic and chemically induced models.

  2017cited by this paper
• Identification of microRNAs involved in gefitinib resistance of non-small-cell lung cancer through the insulin-like growth factor receptor 1 signaling pathway

  2017cited by this paper
• miR-539 inhibits human colorectal cancer progression by targeting RUNX2.

  2017cited by this paper
• Oral Squamous Cell Carcinoma: Current Treatment Strategies and Nanotechnology-Based Approaches for Prevention and Therapy.

  2016cited by this paper
• miR-539 inhibits prostate cancer progression by directly targeting SPAG5

  2016cited by this paper
• miR‐539 induces cell cycle arrest in nasopharyngeal carcinoma by targeting cyclin‐dependent kinase 4

  2015cited by this paper
• MicroRNAs as Potential Biomarkers in Cancer: Opportunities and Challenges

  2015cited by this paper
• ANGPTL3 is a novel biomarker as it activates ERK/MAPK pathway in oral cancer

  2015cited by this paper
• Sox4 participates in the modulation of Schwann cell myelination

  2015cited by this paper
• MicroRNA-539 suppresses osteosarcoma cell invasion and migration in vitro and targeting Matrix metallopeptidase-8.

  2015cited by this paper
• Early Diagnosis and Treatment of Squamous Cell Carcinoma A Case Comparison Highlighting its Importance

  2015cited by this paper
• MiR-539 inhibits thyroid cancer cell migration and invasion by directly targeting CARMA1.

  2015cited by this paper
• Techniques for early diagnosis of oral squamous cell carcinoma: Systematic review

  2015cited by this paper
• Identification of a microRNA signature associated with risk of distant metastasis in nasopharyngeal carcinoma

  2015cited by this paper
• MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer

  2014cited by this paper
• MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking

  2014cited by this paper
• MicroRNAs in osteosarcoma: diagnostic and therapeutic aspects

  2013cited by this paper
• Aberrant microRNA expression in multiple myeloma

  2013cited by this paper
• Quercetin Suppresses Drug-Resistant Spheres via the p38 MAPK–Hsp27 Apoptotic Pathway in Oral Cancer Cells

  2012cited by this paper
• The hallmarks of cancer

  2012cited by this paper
• MicroRNA-1826 directly targets beta-catenin (CTNNB1) and MEK1 (MAP2K1) in VHL-inactivated renal cancer.

  2012cited by this paper
• MicroRNA-409 suppresses tumour cell invasion and metastasis by directly targeting radixin in gastric cancers

  2012cited by this paper
• Intronic miR-26b controls neuronal differentiation by repressing its host transcript, ctdsp2.

  2012cited by this paper
• Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.

  2012cited by this paper
• The miRNA-drug resistance connection: a new era of personalized medicine using noncoding RNA begins.

  2012cited by this paper
• A Potential Regulatory Role for Intronic microRNA-338-3p for Its Host Gene Encoding Apoptosis-Associated Tyrosine Kinase

  2012cited by this paper
• Genetics/epigenetics of oral premalignancy: current status and future research.

  2011cited by this paper
• ERK/MAPK pathways play critical roles in EGFR ligands-induced MMP1 expression.

  2011cited by this paper
• Role of Ras/Raf/MEK/ERK signaling in physiological hematopoiesis and leukemia development

  2011cited by this paper
• Squamous cell carcinoma and precursor lesions of the oral cavity: epidemiology and aetiology.

  2011cited by this paper
• Developing therapeutic microRNAs for cancer

  2011cited by this paper
• Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.

  2011cited by this paper
• HPV-associated head and neck cancer: a virus-related cancer epidemic.

  2010cited by this paper
• Cancer of the oral cavity and oropharynx

  2010cited by this paper
• OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma

  2010cited by this paper
• miR-24 up-regulation in oral carcinoma: positive association from clinical and in vitro analysis.

  2010cited by this paper
• MiR-21 Indicates Poor Prognosis in Tongue Squamous Cell Carcinomas as an Apoptosis Inhibitor

  2009cited by this paper
• Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study

  2009cited by this paper
• Dysregulated molecular networks in head and neck carcinogenesis.

  2009cited by this paper
• MicroRNA polymorphisms: the future of pharmacogenomics, molecular epidemiology and individualized medicine.

  2009cited by this paper
• MiR-24 Tumor Suppressor Activity Is Regulated Independent of p53 and through a Target Site Polymorphism

  2009cited by this paper
• MEK1 mutations, but not ERK2 mutations, occur in melanomas and colon carcinomas, but none in thyroid carcinomas

  2009cited by this paper
• Multiple pathways in the FGF signaling network are frequently deregulated by gene amplification in oral dysplasias

  2009cited by this paper
• miRDB: a microRNA target prediction and functional annotation database with a wiki interface.

  2008cited by this paper
• The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis

  2008cited by this paper
• Association between High miR-211 microRNA Expression and the Poor Prognosis of Oral Carcinoma

  2008cited by this paper
• Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.

  2008cited by this paper
• A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance

  2007cited by this paper
• Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance.

  2007cited by this paper
• Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

  2007cited by this paper
• Oncomirs — microRNAs with a role in cancer

  2006cited by this paper
• Integrating signals between cAMP and the RAS/RAF/MEK/ERK signalling pathways

  2005cited by this paper
• Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets.

  2005cited by this paper
• Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer.

  2004cited by this paper
• Pharmacogenetics and disease genetics of complex diseases

  2003cited by this paper
• Publisher's Note

  2003cited by this paper
• MAPK signal pathways in the regulation of cell proliferation in mammalian cells

  2002cited by this paper
• Four deaths and a funeral: from caspases to alternative mechanisms

  2001cited by this paper
• Fas triggers an alternative, caspase-8–independent cell death pathway using the kinase RIP as effector molecule

  2000cited by this paper
• Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors

  1999cited by this paper
• Signal transduction pathways activated and required for mammary carcinogenesis in response to specific oncogenes

  1998cited by this paper
• Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms

  1995cited by this paper
• Lipopolysaccharide Signals Activation of Tumor Necrosis Factor Biosynthesis Through the Ras/Raf-1/MEK/MAPK Pathway

  1994cited by this paper
• The primary structure of MEK, a protein kinase that phosphorylates the ERK gene product.

  1992cited by this paper

• No citing papers are available for this paper.